Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 213

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 213
---
’s Chief Scientific Officer Prof. Eric Vivier, and Chief Development Officer, Nicola Beltraminelli.

Sonia Quaratino, current Executive Vice President, Chief Medical Officer and member of the Leadership Team was appointed to the Executive Board. Sonia Quaratino joined Innate Pharma in October 2023, bringing over 25 years of experience in basic research, clinical development, and translational medicine, having worked in academia, global large pharmaceuticals, and biotech companies.

Arvind Sood, Executive Vice President, President of US operations, was a member of the Executive Board and of the Leadership Team, and was responsible for the execution of the Company’s U. S. strategy, to help expand the Company’s U. S. investor base, and source business development and corporate development opportunities in the U. S. including liaising with academic institutions and clinical key opinion leaders. Arvind Sood joined Innate Pharma from Amgen after over four decades of experience within large biopharma companies in areas including commercial operations, investor relations and financial communications. Arvind Sood left the Company in February 2025 and resigned from his position as member of the Executive Board. The position of President of U. S. Operations is not contemplated to be filled at this time. The Company and Mr. Sood are discussing his departure conditions.

Family Relationships

There are no family relationships among any of the members of the Executive Board, the Supervisory Board, and the Leadership Team of the Company referred to above.

Arrangements with existing Major Shareholders and Customers

There are no arrangements with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as member of the Executive Board, the Supervisory Board, or of the Leadership Team of the Company.

Subsequent Developments

The Company plans to ask to the next General Meeting to be held on May 22, 2025 to approve its transformation into a société anonyme with a Board of Directors (" conseil d'administration"). This transformation is part of a strategic move to simplify and align Innate Pharma's corporate governance with international standards.

If the General Meeting approves this governance change, it will be asked to appoint as members to the Board of Directors, Irina Staatz-Granzer, Pascale Boissel, Sally Bennett, Véronique Chabernaud, Bpifrance (represented by Olivier Martinez), Jonathan Dickinson and two new members of the Board of Directors, Marty J. Duvall and Christian It